Barclays analyst Steve Valiquette lowered the firm’s price target on Healthcare Realty Trust to $24 from $28 and keeps an Overweight rating on the shares. The analyst is seeing "greater deviation" in medical office building real estate investment trust performance both operationally and from a valuation perspective exiting 2022 and into 2023. Healthcare Realty is growing faster than peers, but trades at valuation discount, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HR:
- Sell these stocks now, proven algorithm says
- Healthcare Realty Trust downgraded to Neutral from Outperform at Credit Suisse
- Healthcare Realty Trust Reports Results for the Fourth Quarter
- Healthcare Realty Trust reports Q4 normalized FFO 42c, consensus 40c
- Healthcare Realty Trust Announces Quarterly Dividend
